We take your privacy very seriously, please consent to the use of all cookies when visiting our website. for more information on the processing of personal data, please refer to the Privacy Policy.

EN
Make an Appointment
c4_ban.png c4_ban_ph.png

Department of Neurology
Alzheimer's Disease

  • Technical Advantages
  • Equipment Advantages
  • Leading Experts
  • Treatment Cases

Technical Advantages

Technical Advantages

The Department of Neurology excels in the precise diagnosis and treatment of Alzheimer's Disease. The technical advantages are as follows

  • c1_icon_08.svg
    Accurate diagnosis using scales, PET-CT, and AD biomarker testing.
  • c1_icon_08.svg
    Disease-modifying therapy with Lecanemab can slow the progression of Alzheimer's Disease.

Equipment Advantages

Equipment Advantages

  • 1
    PET-CT: Visualizes the spatial distribution of beta-amyloid plaques (excessive accumulation of amyloid plaques in the brain is causally linked to memory and thinking problems associated with Alzheimer's Disease)
  • 2
    AD Biomarker Testing: Precise detection
  • 3
    Lecanemab: A targeted therapeutic drug that precisely binds to deposited beta-amyloid in the brain, effectively clearing excessive beta-amyloid plaques and slowing the progression of Alzheimer's Disease
a7_mdt2.jpg

Leading Experts

View All Experts
刘惠卿.png
Liu Huiqing
Chief Physician, Doctor of Medicine, Professor, Master's Supervisor
Professional Resume

Prof. Liu specializes in the rescue and management of critically ill patients with cerebrovascular diseases, encephalitis, and status epilepticus. She is particularly skilled in electroencephalography (EEG) technology and the treatment of intractable epilepsy. She also excels in the diagnosis and treatment of common, frequent, and complex neurological disorders.

Areas of Expertise
Scan WeChat Code to Book 刘惠卿.jpg

Clinical Cases

  • 20250717220151154.webp

    Retrieving "Lost" Memories: An Octogenarian Alzheimer's Patient "Restarts" Life!

    • Patient Profile

      An 80-year-old male

    • Chief Complaints

      Began experiencing memory decline 4 years ago, with poor spatial recognition and a tendency to get lost. In severe cases, he could not recognize relatives other than his children.

    • Treatment Process

      Diagnosed with mild cognitive impairment due to Alzheimer's Disease through cognitive scale assessment and MRI. The Department of Neurology at HeYou Hospital, in collaboration with the Department of Imaging and other specialties through multidisciplinary consultation, assessed his eligibility for Lecanemab treatment. After multiple Lecanemab treatments, the patient's symptoms significantly improved, with clear speech, regained reading ability, and improved mobility.

    • Technical Highlights

      1. Multidisciplinary diagnosis, utilizing PET-CT, AD biomarker testing, and other methods for precise diagnosis

      2. Use of the newly approved amyloid-beta protein plaque-targeting drug Lecanemab in China